Hi Rebekah,
Apologies.. Sorry, u are correct. I just went back and had a look at some old notes I had regarding the trials. The two trials were ATH 202 & ATH 201. The one due in July was the "open label study," and the one that concludes in November of this year is the "Double Blind Placebo Study" results due in mid-January 2025. As for the bioMUSE study, its what they used to recruit patients for the trials. The mistake that was made last time round was that they had PD sufferers used in our trials, and our drug was perceived to be ineffective as PD sufferers have a slower decline than MSA sufferers.
With the "Open Label Study," Scientists are able to communicate openly with Patients on how they feel and are able to adjust the trial accordingly based on patient and data feedback.
Hi Rebekah,Apologies.. Sorry, u are correct. I just went back...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $2.401K | 800.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 110142186 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 150940914 | 62 |
View Market Depth
| Last trade - 10.20am 08/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |